Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 7/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745806 | 1.00 | ICMT (0.41) | ICMTGRIN2BKMT2ACNR1MAPT | |
| Hydrochloric Acid SCHEMBL23721889 | 0.99 | ICMT (0.41) | ICMTGRIN2BKMT2ACNR1MAPT | |
| SCHEMBL23745854 | 0.93 | ICMT (0.42) | ICMTGRIN2BKMT2ACNR1MAPT | |
| SCHEMBL23745855 | 0.93 | ICMT (0.42) | ICMTGRIN2BKMT2ACNR1MAPT | |
| SCHEMBL23722107 | 0.92 | ICMT (0.48) | ICMTGRIN2BKMT2ACNR1CCR1 | |
| SCHEMBL23745742 | 0.92 | ICMT (0.48) | ICMTGRIN2BKMT2ACNR1CCR1 | |
| SCHEMBL23745578 | 0.91 | ICMT (0.49) | ICMTKMT2AKRAS | |
| Hydrochloric Acid SCHEMBL23721849 | 0.91 | ICMT (0.47) | ICMTGRIN2BKMT2ACNR1CCR1 | |
| Hydrochloric Acid SCHEMBL23722012 | 0.89 | ICMT (0.41) | ICMTKMT2ACNR1CCR1KRAS | |
| SCHEMBL23745594 | 0.88 | CNR1 (0.42) | ICMTKMT2ACNR1MAPTCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | ICMT 345/4885GRIN2B 4667/4885KMT2A 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.